This trial is testing a new cancer vaccine in adults with metastatic cancer. The vaccine consists of two parts, given a few weeks apart. The first part is given as an injection, and the second part is given as a smallpox-like rash. The trial will test for safety and efficacy.
7 Primary · 4 Secondary · Reporting Duration: Through study completion, an average of 2 years
115 Total Participants · 5 Treatment Groups
Primary Treatment: GAd20-209-FSP, RP2D · No Placebo Group · Phase 1 & 2
Age 18 - 85 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: